In preparation for our FDA submission for Phase I Human Trials, Biopep is excited to report that we have contracted with BRI Biopharmaceuticals Research Inc. to further analyze the intrinsic qualities of LSE.
This study will include an in-depth analysis of:
- LSE drug consistency
- LSE drug efficacy including protein marker selection
- LSE drug safety including immunotoxicity studies
- Chemistry, manufacturing and controls of drug substance
- Establishment of an Aquatic Vivarium and Leeches Husbandry
